Analysts expect Kodiak Sciences Inc. (NASDAQ:KOD) to report $-0.35 EPS on August, 21.After having $-0.21 EPS previously, Kodiak Sciences Inc.’s analysts see 66.67 % EPS growth. The stock increased 0.17% or $0.02 during the last trading session, reaching $11.72. About 81,317 shares traded. Kodiak Sciences Inc. (NASDAQ:KOD) has 0.00% since August 9, 2018 and is . It has by 0.00% the S&P500.

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company has market cap of $432.61 million. The company’s lead product candidate is KSI-301, a vascular endothelial growth factor -biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. It currently has negative earnings. The Company’s preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD.

More notable recent Kodiak Sciences Inc. (NASDAQ:KOD) news were published by: which released: “The Week Ahead In Biotech: Pharma Earnings Pick Up Pace – Benzinga” on July 20, 2019, also with their article: “Kodiak Sciences Inc. (KOD) Shares March Higher, Can It Continue? – Nasdaq” published on June 17, 2019, published: “Is Gold Resource Corporation (GORO) A Good Stock To Buy? – Yahoo Finance” on June 29, 2019. More interesting news about Kodiak Sciences Inc. (NASDAQ:KOD) were released by: and their article: “The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes – Benzinga” published on June 13, 2019 as well as‘s news article titled: “Kodiak Sciences Files For $100 Million IPO – Seeking Alpha” with publication date: September 12, 2018.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *